Breast cancer prognostication and prediction in the postgenomic era.
about
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesPerformance characteristics of ultrasound-guided fine-needle aspiration of axillary lymph nodes for metastatic breast cancer employing rapid on-site evaluation of adequacy: analysis of 136 cases and review of the literatureThe p53-estrogen receptor loop in cancerCHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancerUnraveling the microenvironmental influences on the normal mammary gland and breast cancerMass spectrometry-based analysis of therapy-related changes in serum proteome patterns of patients with early-stage breast cancer.Tailored targeted therapy for all: a realistic and worthwhile objective?Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancersAre current development programs realising the full potential of new agents?Morphologic complexity of epithelial architecture for predicting invasive breast cancer survival.Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer.The multitude of molecular analyses in cancer: the opening of Pandora’s box.Effects of berberine on proliferation, cell cycle distribution and apoptosis of human breast cancer T47D and MCF7 cell lines.Poor-prognosis estrogen receptor- positive disease: present and future clinical solutionsLow expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survivalStrength and weakness of phase I to IV trials, with an emphasis on translational aspects.A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamidePrediction of breast cancer metastasis by genomic profiling: where do we stand?Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanomaMolecular basis for therapy resistance.Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy.Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.Impact of axillary ultrasound (AUS) on axillary dissection in breast conserving surgery (BCS).Fractal dimension and lacunarity of tumor microscopic images as prognostic indicators of clinical outcome in early breast cancer.Gray-Level Co-Occurrence Matrix Texture Analysis of Breast Tumor Images in Prognosis of Distant Metastasis Risk.Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.Is there an association between invasive lobular carcinoma of the breast and a family history of gastric cancer?Adjuvant treatment: the contribution of expression microarrays.
P2860
Q26743510-AC6B4DFA-9040-40C4-AECE-06681318CCEEQ26852867-B5C716C7-358D-4D4A-A1AD-720A9B1EF6DBQ27027865-46105F01-2B52-41CA-8E10-F794036B753EQ28473504-F2AB6D5B-F3D4-4AE8-9C0F-0439A4D07866Q28473677-F1561023-D1E3-4172-9E7D-F5C604BFACE3Q30985472-DAEABDB7-9D2A-4C50-A027-1DB6285479CAQ33555473-E989BF78-0050-4342-8CA8-FFED73106357Q33893910-6EC7489A-A348-4C0A-BE65-5AAB221ED69EQ34013967-A8037472-861E-4EA3-A8AF-1101BEE64C10Q34423576-2716A44D-98F1-4CAA-B032-499396DAA18EQ34506605-1B21AFDF-B9D6-469D-B1F3-506F7EB8A5DFQ34825969-C2B6288B-BB2A-48E8-8E7B-EB6F7F94E27FQ35332888-FF345D80-0BE5-4489-AC5C-671A1DE88188Q35630466-E89BB689-2A79-4ABE-98E7-0E3575F29A8CQ35949291-D2A577BE-5F37-4BBA-B6AC-567DFAE2CE5BQ36245541-DCAFACA3-21A9-4836-A7CD-190C69D6B38BQ36924468-DE69C7DE-869A-4D6F-A7E4-1C0DDA57CAE4Q37039810-C271896E-F4CC-4C7B-8C30-288DA9D30E73Q37229749-5AF96F99-F2EA-4B55-B7D0-28043026C750Q37279681-861D8F6B-21CD-458B-AC00-BE3FB2BE4AC4Q37334055-47A6DFB6-92F4-457D-8489-617CE4E65F6AQ37751530-AA4D4B2F-FF60-4C0F-9191-5667DBBD6C78Q38047337-811AD5C7-1C68-4785-8604-2C3F5346EF5BQ38087850-4E1E3371-EEE8-41A5-B4DE-708A00E4CCA8Q38370848-B0002353-F6D6-4B0A-B53B-16B5D01850F2Q38383326-983D628C-BEE8-4551-865D-E81DFE32E659Q40270909-52741918-EC8F-4DFF-B42C-FB8577D636B4Q40907746-33A6DF8D-7F85-4E1B-9032-841E1CE11E6BQ41377330-955DF675-8E77-4611-9542-70BA405F125CQ45788484-BFB45C7F-8856-4923-9C2B-CF96015B2DDE
P2860
Breast cancer prognostication and prediction in the postgenomic era.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Breast cancer prognostication and prediction in the postgenomic era.
@ast
Breast cancer prognostication and prediction in the postgenomic era.
@en
type
label
Breast cancer prognostication and prediction in the postgenomic era.
@ast
Breast cancer prognostication and prediction in the postgenomic era.
@en
prefLabel
Breast cancer prognostication and prediction in the postgenomic era.
@ast
Breast cancer prognostication and prediction in the postgenomic era.
@en
P2093
P356
P1433
P1476
Breast cancer prognostication and prediction in the postgenomic era.
@en
P2093
J R Lillehaug
R Chrisanthar
V Staalesen
P304
P356
10.1093/ANNONC/MDM013
P577
2007-02-21T00:00:00Z